{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:33:06Z","timestamp":1762543986417,"version":"3.37.3"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.vph.2024.107374","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T16:23:34Z","timestamp":1713457414000},"page":"107374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Gaps in evidence in the management of patients with intermediate-risk pulmonary arterial hypertension: Considerations following the ESC\/ERS 2022 guidelines"],"prefix":"10.1016","volume":"155","author":[{"given":"Michele","family":"D'Alto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Badagliacca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo","family":"Air\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Ameri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Argiento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Garascia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo Mario","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Mul\u00e8","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Raineri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Scelsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine Dario","family":"Vizza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Ghio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2022","key":"10.1016\/j.vph.2024.107374_bb0005"},{"key":"10.1016\/j.vph.2024.107374_bb0010","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1093\/eurheartj\/ehx257","article-title":"A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension","volume":"39","author":"Kylhammar","year":"2018","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.vph.2024.107374_bb0015","doi-asserted-by":"crossref","first-page":"1700889","DOI":"10.1183\/13993003.00889-2017","article-title":"Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension","volume":"50","author":"Boucly","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.vph.2024.107374_bb0020","doi-asserted-by":"crossref","first-page":"1700740","DOI":"10.1183\/13993003.00740-2017","article-title":"Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model","volume":"50","author":"Hoeper","year":"2017","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.vph.2024.107374_bb0025","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.vph.2024.107374_bb0030","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029024","article-title":"Revised definition of pulmonary hypertension and approach to management: a clinical primer","volume":"12","author":"Maron","year":"2023","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.vph.2024.107374_bb0035","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.vph.2024.107374_bb0040","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.healun.2008.02.009","article-title":"Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension","volume":"27","author":"Rosenzweig","year":"2008","journal-title":"J. Heart Lung Transplant."},{"issue":"12","key":"10.1016\/j.vph.2024.107374_bb0045","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1164\/rccm.200712-1807OC","article-title":"Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation","volume":"177","author":"Sztrymf","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.vph.2024.107374_bb0050","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S2213-2600(15)00544-5","article-title":"BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis","volume":"4","author":"Evans","year":"2016","journal-title":"Lancet Respir. Med."},{"issue":"4","key":"10.1016\/j.vph.2024.107374_bb0055","doi-asserted-by":"crossref","DOI":"10.1177\/20458940211037275","article-title":"BMPR2 mutations and response to inhaled or parenteral prostanoids: a case series","volume":"11","author":"Scelsi","year":"2021","journal-title":"Pulm Circ."},{"issue":"17","key":"10.1016\/j.vph.2024.107374_bb0060","first-page":"32041","article-title":"Prognostic relevance of right heart reverse remodeling in idiopathic pulmonary arterial hypertension","volume":"S1053-2498","author":"Badagliacca","year":"2017","journal-title":"J. Heart Lung Transplant."},{"issue":"4","key":"10.1016\/j.vph.2024.107374_bb0065","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1164\/rccm.202004-1006OC","article-title":"Risk reduction and hemodynamics with initial combination therapy in pulmonary arterial hypertension","volume":"203","author":"Badagliacca","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.vph.2024.107374_bb0070","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.chest.2019.02.004","article-title":"Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC\/ERS-based risk assessment strategies","volume":"156","author":"Benza","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.vph.2024.107374_bb0075","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1378\/chest.14-0701","article-title":"Signs of right ventricular deterioration in clinically stable patients with pulmonary arterial hypertension","volume":"147","author":"van de Veerdonk","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.vph.2024.107374_bb0080","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009101","article-title":"Invasive right ventricular pressure-volume analysis: basic principles, clinical applications, and practical recommendations","volume":"15","author":"Brener","year":"2022","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.vph.2024.107374_bb0085","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijcard.2018.01.053","article-title":"Relevance of the TAPSE\/PASP ratio in pulmonary arterial hypertension","volume":"266","author":"Tello","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.vph.2024.107374_bb0090","article-title":"Validation of the tricuspid annular plane systolic excursion\/systolic pulmonary artery pressure ratio for the assessment of right ventricular-arterial coupling in severe pulmonary hypertension","volume":"12","author":"Tello","year":"2019","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"10.1016\/j.vph.2024.107374_bb0095","doi-asserted-by":"crossref","first-page":"H1373","DOI":"10.1152\/ajpheart.00157.2013","article-title":"Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis","volume":"305","author":"Guazzi","year":"2013","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"10 Pt B","key":"10.1016\/j.vph.2024.107374_bb0100","article-title":"RV contractile function and its coupling to pulmonary circulation in heart failure with preserved ejection fraction: stratification of clinical phenotypes and outcomes","volume":"10","author":"Guazzi","year":"2017","journal-title":"JACC Cardiovasc. Imaging"},{"key":"10.1016\/j.vph.2024.107374_bb0105","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/ehjci\/jex133","article-title":"Right ventricularvascular coupling in heart failure with preserved ejection fraction and pre- vs post-capillary pulmonary hypertension","volume":"19","author":"Gorter","year":"2018","journal-title":"Eur Heart J CardiovascImaging"},{"issue":"12","key":"10.1016\/j.vph.2024.107374_bb0110","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.healun.2022.09.005","article-title":"Interest of TAPSE\/sPAP ratio for noninvasive pulmonary arterial hypertension risk assessment","volume":"41","author":"Fauvel","year":"2022","journal-title":"J. Heart Lung Transplant."},{"issue":"26","key":"10.1016\/j.vph.2024.107374_bb0115","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.vph.2024.107374_bb0120","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S2213-2600(20)30532-4","article-title":"Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial","volume":"9","author":"Hoeper","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.vph.2024.107374_bb0125","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.healun.2017.09.024","article-title":"Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: insights from the prostacyclin (PGI2) receptor agonist in pulmonary arterial hypertension (GRIPHON) study","volume":"37","author":"Preston","year":"2018","journal-title":"J. Heart Lung Transplant."},{"issue":"4","key":"10.1016\/j.vph.2024.107374_bb0130","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.healun.2021.01.006","article-title":"Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE","volume":"40","author":"Kim","year":"2021","journal-title":"J. Heart Lung Transplant."},{"issue":"1","key":"10.1016\/j.vph.2024.107374_bb0135","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s12325-021-01898-1","article-title":"Long-term survival, safety and tolerability with Selexipag in patients with pulmonary arterial hypertension: results from GRIPHON and its open-label extension","volume":"39","author":"Gali\u00e8","year":"2022","journal-title":"Adv. Ther."},{"key":"10.1016\/j.vph.2024.107374_bb0140","article-title":"Riociguat treatment in patients with pulmonary arterial hypertension: final safety data from the EXPERT registry","volume":"177","author":"Hoeper","year":"2020","journal-title":"Respir. Med."},{"issue":"23","key":"10.1016\/j.vph.2024.107374_bb0145","doi-asserted-by":"crossref","first-page":"7136","DOI":"10.3390\/jcm11237136","article-title":"Left heart disease phenotype in elderly patients with pulmonary arterial hypertension: insights from the Italian PATRIARCA registry","volume":"11","author":"Toma","year":"2022","journal-title":"J. Clin. Med."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189124001009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189124001009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T12:56:32Z","timestamp":1733403392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189124001009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":29,"alternative-id":["S1537189124001009"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2024.107374","relation":{},"ISSN":["1537-1891"],"issn-type":[{"type":"print","value":"1537-1891"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gaps in evidence in the management of patients with intermediate-risk pulmonary arterial hypertension: Considerations following the ESC\/ERS 2022 guidelines","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2024.107374","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107374"}}